

Financial Disclosures

The National Institutes of Health, Centers for Disease Control and Prevention, our planners, and our presenters wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters, with the exception of the following:

Name	Organization	Nature of Conflict of Interest AND Mechanism to Resolve*
Clauw, Daniel J.	Abbott, Astra Zeneca, Cerephex, Cypress Biosciences, Eli Lilly, Forest, Iroko, Jazz, Johnson & Johnson, Merck, Nuvo, Pfizer, Pierre Fabre, Theravance, Tonix, UCB, University of Michigan, and Wyeth	Research funding, consulting fees, licensing fees, and honorarium.
Kogelnik, Andreas M.	Open Medicine Institute	Salary and stock ownership.
Snell, Christopher R.	WorkWell Foundation	Consultant.

*All other planners, speakers, and panelists signed statements that they have no financial or other conflicts of interest pertaining to the topic under consideration.

There is no commercial support for this activity.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of presentations by Nancy G. Klimas, M.D., Andreas M. Kogelnik, M.D., Ph.D., and Heidi D. Nelson, M.D., M.P.H. Dr. Klimas's review of the current literature of biomarker discovery may include biomarkers that are not yet licensed for this application. Dr. Kogelnik's presentation may include a discussion of his clinic's use of several medications beyond their approved indications. Dr. Nelson's presentation on the results of a systematic review of treatments for ME/CFS will include trials of medications that are investigational or off-label.

NIH Pathways to Prevention Workshop:

Advancing the Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)